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PENILAIAN IMPAK INTERVENSI DI RUMAH OLEH AHLI FARMASI 
DALAM KALANGAN PENGHIDAP DIABETES JENIS 2 DI SATU PUSAT 
PENJAGAAN KESIHATAN AWAM DI BUKIT MINYAK, PULAU PINANG 
MALAYSIA 
 
ABSTRAK 
 
Kencing manis adalah salah satu penyakit tak berjangkit yang paling biasa di 
dunia. Kencing manis jenis 2 merangkumi 90-95% daripada populasi kencing manis. 
Kencing manis jenis 2 yang tidak terkawal akan menyebabkan komplikasi yang teruk. 
Di Malaysia, dalam masa 4 tahun terdapat peningkatan sebanyak 3.6% penyakit 
kencing manis di kalangan dewasa > 18 tahun. Penyakit kencing manis jenis 2 
memerlukan penjagaan berterusan namun dalam kebanyakan kes terdapat kehilangan 
kesinambungan penjagaan pesakit-pesakit kencing manis jenis 2 sebaik sahaja 
mereka meninggalkan pusat penjagaan kesihatan. Oleh itu , kajian ini adalah untuk 
menilai kesan intervensi di rumah oleh pegawai farmasi di kalangan pesakit kencing 
manis jenis 2 di Bukit Minyak klinik di Pulau Pinang, Malaysia. Pesakit yang 
berumur 18 tahun ke atas dan disahkan menghidap kencing manis jenis 2 dengan 
HbA1c > 6.5 % yang mengambil tiga atau lebih ubat-ubatan jangka panjang untuk 
penyakit kencing manis, tekanan darah tinggi atau hyperlipidaemia, tinggal di rumah 
yang mempunyai alamat kediaman tetap serta nombor telefon, dapat memahami 
Bahasa Malaysia, Bahasa Inggeris atau Cina dan bersedia untuk mengambil bahagian 
telah diambil. Pesakit yang telah bersetuju untuk mengambil bahagian dalam kajian 
ini telah dibahagikan kepada kumpulan intervensi [(IG) yang terdiri dua lawatan 
rumah oleh pegawai farmasi] atau kumpulan kawalan [(CG) tiada lawatan ke rumah 
telah disediakan] menggunakan lambungan duit syiling. Pesakit dalam kumpulan 
intervensi menerima sesi pendidikan, kajian ubat-ubatan dan pemantauan tekanan 
darah dan gula semasa lawatan rumah. Tiada intervensi diberikan kepada kumpulan 
xviii 
 
kawalan. Pesakit dalam kedua-dua kumpulan telah dinilai pada kepatuhan ubat dan 
pengetahuan degan menggunakan MMAS-8 dan MDKT soal selidik semasa 
pendaftaran dan penilaian akhir bagi kumpulan kawalan dan lawatan rumah ke-2 
bagi kumpulan intervensi. Secara umum, pesakit dalam kedua-dua kumpulan 
mempunyai kepatuhan ubat yang rendah dan kekurangan pengetahuan mengenai 
kencing manis. Walau bagaimanapun, selepas intervensi di rumah, pesakit dalam 
kumpulan intervensi menunjukkan peningkatan yang ketara dalam HbA1c (-0.73 ± 
1.50), tekanan darah diastolik (-1.19 ± 9.96) , jumlah kolesterol (-0.45 ± 1.16), 
trigliserida (-0.14 ± 0.48), kepatuhan ubat (3.37 ± 1.67) dan pengetahuan (5.84 ± 
1.90) berbanding dengan kumpulan kawalan, p < 0.05. Seramai 202 masalah 
berkaitan uabt yang dikenalpasti semasa lawatan pertama ke rumah pesakit dengan 
purata (3.37 ± 2.99) masalah  setiap pesakit yang dilawati. Empat puluh lapan 
daripada 60 pesakit (80%) mempunyai sekurang-kurangnya satu masalah berkaitan 
ubat. Daripada ubat-ubatan yang berlebihan dikumpul, sejumlah RM 2.805,50 (USD 
770,38) dengan purata RM 47.55 (USD 13.06) setiap pesakit telah dikira daripada 59 
pesakit. Metformin merupakan ubat yang paling banyak kuantiti yang berlebihan di 
rumah pesakit. Kajian ini telah menunjukkan bahawa intervensi di rumah oleh 
pegawai farmasi mampu meningkatkan hasil klinikal, pematuhan ubatan dan 
pengetahuan pesakit. 
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EVALUATION OF PHARMACIST-LED HOME-BASED INTERVENTION 
AMONG TYPE 2 DIABETES PATIENTS FROM A PUBLIC PRIMARY 
CARE CENTRE AT BUKIT MINYAK, PENANG MALAYSIA 
ABSTRACT 
Diabetes mellitus is one of the most common non-communicable diseases in 
the world. Type 2 diabetes mellitus account for 90-95% of the diabetes population. 
Uncontrolled type 2 diabetes has severe complications. In Malaysia, within four 
years there was an increase of 3.6% of adults aged > 18 had diabetes mellitus. Type 2 
diabetes mellitus required continuous care management, however in most cases there 
is a lost of continuity of care in type 2 diabetes mellitus patients once they left the 
healthcare facilities. Studies have shown a high incidence of drug-related problems 
among patients who had discharged from healthcare facilities. Thus, this study was 
to evaluate the impact of pharmacist-led home-based intervention among type 2 
diabetes patients at Bukit Minyak clinic in Penang, Malaysia. This was a randomised 
controlled trial conducted in Bukit Minyak clinic. Patients aged 18 years and above 
and diagnosed with T2DM with the most recent HbA1c >6.5%, currently taking 
three or more long term medications for diabetes, hypertension or hyperlipidaemia, 
staying at house with permanent residential address and telephone number, able to 
understand Bahasa Malaysia, English or Chinese and willing to participate were 
recruited. Patients who were agreed to participate in the study were assigned to either 
the intervention group [(IG), which consisted a two home visits by the pharmacist] or 
control group [(CG) where no home visit was provided] using a coin tossing. Patients 
in the intervention group received educational sessions, medication review and point 
of care for blood pressure, cholesterol and sugar monitoring during the home visits. 
There was no intervention given to the control group. Patients in both groups were 
assessed on their medication adherence and knowledge using the validated MMAS-8 
xx 
 
and MDKT questionnaire during the enrolment and final assessment for the control 
group and 2
nd
 home visit for the intervention group. In general, patients in both 
groups had low medication adherence and poor knowledge on diabetes. However, 
after the home-based intervention, patients in the intervention group had significant 
improvement in HbA1c (-0.73 ± 1.50), diastolic blood pressure (-1.19 ± 9.96), total 
cholesterol (-0.45 ± 1.16), triglyceride (-0.14 ± 0.48), medication adherence score 
(3.37 ± 1.67) and knowledge score (5.84 ± 1.90) compared to the control group, p < 
0.05. A total of 202 drug related problems identified during the first visit with an 
average of (3.37 ± 2.99) DRP per visited patient. Forty eight out of 60 patients (80%) 
have at least one DRP. From the excessive medications collected, a total cost of RM 
2805.50 (USD 770.38) with an average of RM 47.55 (USD 13.06) per patient was 
calculated from 59 patients. Metformin was the drug with most excess quantities in 
patient’s house. This study had indicated that pharmacist-led home-based 
intervention is able to improve patients’ medication adherence, knowledge and 
clinical outcomes.   
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CHAPTER 1: GENERAL INTRODUCTION  
 
1.1 Background of the study  
Diabetes mellitus (DM) is one of the chronic non-communicable diseases around the 
world. It is the fourth leading cause of mortality in developed and developing 
countries. Recently, it was estimated that there were 382 million people around the 
world have DM and it is projected that the number will increase to 592 million in 
2035 (International Diabetes Federation, 2013). Diabetes mellitus generally can be 
divided into type 1 DM (T1DM), type 2 DM (T2DM) and gestational DM (GDM) 
(International Diabetes Federation, 2013). Type 2 DM is the most common type of 
DM and it accounted about 90-95% of the cases around the world (World Health 
Organization, 2013a). It is estimated that T2DM will increase 55% more in 2035 
(International Diabetes Federation, 2013). Changes in lifestyle, modernisation, 
obesity and changes in population demographic incidence have contributed to the 
increase of type 2 DM (T2DM) (Steiner, 2006).  
Uncontrolled blood sugar level can lead to serious complications such as 
nephropathy, neuropathy, cardiovascular disease and early death (American Diabetes 
Association, 2008, International Diabetes Federation, 2013). Therefore, people with 
T2DM need multiple medications and lifestyle modifications to maintain blood sugar 
at the optimum level and reduce cardiovascular risk (Bailey and Kodack, 2011). 
Although multiple regimens might help to ameliorate the symptoms and improve 
quality of life, but the use of multiple medications can lead to non-adherence, drug 
interactions and others adverse events which the physicians might not be aware of 
(Steinman and Hanlon, 2010). Studies has indicated that inappropriate used of 
medications was one of the most common drug related problems in T2DM patients 
during a medication review and home interview (Ding et al., 2010). Another study on 
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the medication management at home has demonstrated that patients with higher 
number of medications at home were likely to have medication hoarding, duplication 
of therapy and severity of illness (Sorensen et al., 2005). 
In Malaysia, the progression of T2DM has increased at an alarming rate. The overall 
prevalence of adults with diabetes aged > 18 years has increased from 11.6% to 15.2% 
within four years despite the existing treatment guidelines and the availability of the 
healthcare facilities (Institute for Public Health, 2011). There are many factors 
contributing to the increasing trend, one of them is the lack of awareness of the 
patients towards the disease and therapy. Studies conducted in one of the teaching 
hospital in Malaysia has shown that the majority of the T2DM with hypertension 
patients were lack of awareness on the disease, the medications they took and the 
complications of the disease (Letchuman et al., 2010).    
 
1.2 Justification of the study  
Type 2 DM is a chronic illness that requires continuity of medical care, self-
management and support to prevent complication (American Diabetes Association, 
2010, International Diabetes Federation, 2013). Lost in the transition of care, 
especially when patients leave the healthcare facilities could lead to major 
medication related problems such as non-adherence, stock piling at home, taking 
expired medications or taking herbal preparations which might interact with the 
prescribed medications (Cook et al., 2000). The risk of medication related problems 
or drug related problems are higher in patients taking multiple medications and 
discharged from the healthcare settings. Studies have shown that drug related 
problems were common among discharged patients. A study conducted at 112 
community pharmacies in Europe identified a total of 451 drug related problems 
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among 277 patients (Paulino et al., 2004). Another study conducted in a tertiary care 
academic hospital found that a total of 66 patients had adverse events after 
discharged from hospital (Forster et al., 2003). Thus, there is higher risk of 
medication misadventures once patients leave the healthcare facilities back to their 
own house. These conditions become worse when the healthcare system enables 
patients to get their medication up to 6 months without further physician appointment 
(Eichenberger et al., 2011). Furthermore, healthcare providers have difficulties in 
managing T2DM patients that needed continuous follow-up, monitoring, education 
and counselling in a poorly designed healthcare system (Hayward et al., 2005). 
Besides that, long waiting time in the outpatient clinic and a long time lapse between 
the appointments could cause patients to miss their clinic appointments (McDonald 
et al., 2002). In order to obtain complete information on how patients manage their 
medications, it would be useful to visit patients at their homes rather than conducting 
the medication review at the healthcare settings.  
From literature, home medication reviews conducted by pharmacists have 
demonstrated effectiveness in preventing, identifying and resolving drug-related 
problems encountered by the patients (Gilbert et al., 2002, Castelino et al., 2010). A 
retrospective study has shown that patients who received the Medication 
Management Program from pharmacist have lesser resource utilization (Flanagan et 
al., 2010). Similarly in another study conducted in elderly patients who received 
post-discharged home visits within five days had significant lesser drug-related 
problems and hospitalization after ninety days of discharged (Naunton and Peterson, 
2003). However, majority of the studies were conducted in developed countries such 
as UK and Australia in a controlled environment (Lenaghan et al., 2007, Holland et 
al., 2005, Jackson et al., 2004). With the differences in social background and 
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cultural believes in Malaysia, the implementation of home-based intervention might 
have different outcomes from other developed countries. Furthermore, there is little 
local study on the impact of the home-based intervention conducted by pharmacist 
on patient’s medication adherence, knowledge and clinical outcomes.  
 
1.3 Study objectives 
The objectives for this study were: 
1) To evaluate the effectiveness of home-based intervention on patient’s   
            medication adherence and general diabetes knowledge among T2DM patients. 
2) To assess the impact of home-based intervention on laboratory biomarkers   
            and economic evaluation  
3) To determine the drug related problems occurring among T2DM patients at  
            their home during home visits.  
4) To evaluate the patients’ view on home-based intervention programme. 
 
1.4 Overview of thesis 
Chapter 2, the literature review, commence with an overview of DM classification, 
the sign, symptoms and complication of T2DM as well as the screening and 
diagnosis of T2DM followed by the elaboration on the non-pharmacological and 
pharmacological treatment for T2DM, the prevalence and the burden of diabetes 
mellitus in Malaysia. The chapter continues with the drug-related problems that 
T2DM patients’ encountered, the awareness and knowledge towards DM, the 
medication adherence in DM as well as the interventions to improve awareness and 
medication adherence. The chapter ends with the discussion on the role of pharmacist 
in diabetes management.  
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Chapter 3 is the general methodology of the study. It includes the study design and 
location, tools used for data collection, data analysis and randomization of the 
patients and implementation of the intervention.  
Chapter 4 elaborates the results of pre-intervention analysis focusing on clinical 
outcomes, patients’ medication adherence and diabetes knowledge among T2DM 
patients. 
Chapter 5 discusses the development, implementation and evaluation of the home-
based intervention.  
Chapter 6 draws the thesis to a conclusion with the overall summary, the 
recommendations for future research and the study limitations.  
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Classification of diabetes mellitus 
Diabetes mellitus (DM) can be classified by the underlying causes. There are three 
main types of DM which are: type 1 DM (T1DM), type 2 DM (T2DM) and 
gestational DM (GDM) (International Diabetes Federation, 2013). In T1DM, the 
insulin is absent due to the autoimmune pancreatic β-cell destruction which might be 
set off by the environmental factor of the genetic susceptible individual (International 
Diabetes Federation, 2013). Pancreatic β-cell destruction occurred over the years, 
however the symptoms developed over a short period of time (International Diabetes 
Federation, 2013). The incidence of T1DM often occurred in the early life, however 
it might appear at any age. Type 1 DM accounted about 5-10% of all diabetes cases 
(American Diabetes Association, 2014a). Patients with T1DM required insulin 
injection (Barceló and Rajpathak, 2001).  
On the other hand, in T2DM, the high sugar level in the bloodstream is due to the 
combination of factors such as insulin resistance or insufficiency of insulin 
production (International Diabetes Federation, 2011). Type 2 DM accounted 90-95% 
of all diabetes in the world and it appears mainly in adults. The main risk factors for 
T2DM are obesity, sedentary lifestyle and over calories intake (International 
Diabetes Federation, 2011). Treatments for T2DM are many, ranging from lifestyle 
modification, oral hypoglycaemic agents (OHA), insulin or a combination of these 
(Barceló and Rajpathak, 2001). Gestational DM (GDM) occurred when high sugar 
level is diagnosed for the first time during pregnancy. It is estimated that nearly 4% 
of all pregnancy is GDM. Furthermore women with GDM have a higher risk of 
developing T2DM in later life (International Diabetes Federation, 2011). Other types 
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of DM could be due to genetic defect on the action of insulin,  pancreas disease, 
infections, surgery or drugs (American Diabetes Association, 2014a).    
    
2.2 Sign, symptoms and complication of type 2 diabetes mellitus 
Hyperglycaemia often marked by symptoms such as polyuria, polydipsia, polyphagia, 
blur vision and weight loss (American Diabetes Association, 2014a). However, these 
symptoms are often asymptomatic for individuals with mild hyperglycaemia or early 
DM (The Merck Manual Professional Edition, 2014). Consequently, the diagnosis 
for these groups of patients is often delayed (International Diabetes Federation, 
2011). Consistently high blood sugar level can lead to long term complications that 
can affect the heart, kidney, nerve and blood vessels however, individuals with 
T2DM often unaware of the long term complications caused by the disease  
(International Diabetes Federation, 2013, American Diabetes Association, 2014b). 
  
2.3 Screening and diagnosis for type 2 diabetes mellitus  
Diabetes mellitus is associated with serious morbidity and mortality. Early detection 
and treatment are crucial in helping to minimize the complications. However, early 
detection comes through screening procedures (International Diabetes Federation, 
2012). Screening is important for high risk individuals to help identify them with 
impaired glucose tolerance or impaired fasting tolerance whom will be benefited 
from the intervention provided to delay the progression of the disease.     
For decades, the diagnosis of diabetes has been based on the fasting blood sugar 
(FBS) with the cut point of ≥ 7mmol/L or the post 2 hours of the 75g of oral glucose 
tolerance test (OGTT) with the threshold of ≥ 11.1 mmol/L or a random plasma 
glucose of ≥ 11.1 mmol/L. Recently, the International Expert Committee had 
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suggested the use of HbA1c with the threshold of ≥ 6.5% as one of the ways to 
diagnose DM. There are advantages of using HbA1c as a diagnosis tool because it is 
more convenient (no fasting needed) and less perturbations during illness (American 
Diabetes Association, 2014a). Table 2.1 shows the criteria for diagnosing DM. 
Nevertheless, the HbA1c test should use a standardized method to execute and this 
might not be practical in all contexts.  
Table 2.1 Criteria for diagnosing DM  
HbA1c ≥ 6.5%. The test should be performed in a laboratory using a method that is 
NGSP certified and standardized to the DCCT assay 
OR 
FPG ≥ 126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 
hours 
OR 
2-hours plasma glucose ≥ 200mg/dL (11.1 mmol/L) during an OGTT. The test 
should be performed as described by the WHO, using a glucose load containing 
equivalent of 75g anhydrous glucose dissolved in water 
OR 
In a patients with classic symptoms of hyperglycaemia or hyperglycaemic crisis, a 
random plasma glucose ≥ 200mg/dL (11.1 mmol/L) 
NGSP = National Glycohemoglobin Standardization Program, DCCT = Diabetes 
Control and Complications Trial, OGTT = Oral Glucose Tolerance Test  
(Adopted from American Diabetes Association, 2014) 
 
 
2.4 Non-pharmacological treatment for type 2 diabetes mellitus  
2.4.1 Weight management  
In treating T2DM, non-pharmacological treatment which include weight loss, diet 
and physical activity still remain the first line approach (Sigal et al., 2006). 
Overweight and obesity are strongly associated with the development of T2DM. In 
fact, there are studies that shown an increased risk in T2DM with increased of body 
mass index (BMI) (Narayan et al., 2007). Furthermore, overweight or obesity can 
increase the prevalence of hyperlipidaemia and hypertension (Crawford et al., 2010). 
Thus weight loss has additional benefit for T2DM because it helps to improve other 
risk factor such as cardiovascular disease by reducing blood pressure and improve 
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serum lipid (Look AHEAD Research Group, 2010). In order to reduce the risk of 
macrovascular and microvascular complication of T2DM, weight loss is 
recommended for individual who have or at risk of having T2DM and is overweight 
(BMI 25.0-29.9 kg/m
2) or obese (BMI ≥ 30 kg/m2) (Klein et al., 2004). A moderate 
weight reduction of 5-10% have shown to improve cardiovascular risk in T2DM 
patients (Wing et al., 2011).  
 
2.4.2 Diet  
Weight loss can only be achieved by reducing the dietary energy consumption or 
increasing the energy expenditure. By reducing the total amount of food consumed or 
selecting food with lower energy density is one of the way to reduce dietary energy 
consumption (Lindström et al., 2006). For T2DM patients, deciding what to eat is the 
most challenging task in their treatment plan (Evert et al., 2013). Even the American 
Diabetes Association (ADA), American Heart Association (AHA), British Diabetes 
Association (BDA), European Association for the Study of Diabetes (EASD), 
Canadian Diabetes Association (CDA), International College of Nutrition, group 
from South Africa and Japan and the National Cholesterol Education Panel (NCEP) 
have different recommendation for optimal diet for T2DM (summarized in Table 
2.2).  In a study that compared a low fat diet with a low carbohydrate Mediterranean-
style diet in newly diagnosed T2DM patients has shown that patients taking low 
carbohydrate Mediterranean-style diet delay the initiation of OHA and have better 
glycaemic control (Esposito et al., 2009). A systematic meta-analysis on the different 
types of dietary approach have concluded that low carbohydrate, low glycaemic 
index (GI), Mediterranean diet and high-protein diet might be effective in improving 
several markers for cardiovascular disease and have better role in T2DM 
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management (Ajala et al., 2013). In Malaysia, a reduced calorie diet (20-25 kcal/kg 
body weight) consisted of 50-60% energy from carbohydrate, 15-20% energy from 
protein, 25-30% energy from fats and a high fibre diet of 20-30g/day are encouraged 
in T2DM patients (Ministry of Health Malaysia, 2009). However, there is no “one-
size-fits-all” dietary pattern for T2DM patients. Individuals with T2DM have to play 
an active role in self-management, education and collaborate with healthcare 
providers for the development of their treatment plan (American Diabetes 
Association, 2010).  
Table 2.2 Recommendation for medical nutrition for diabetes patients 
 
ADA = American Diabetes Association, AHA = American Heart Association,  
BDA= British Diabetes Association, CDA = Canadian Diabetes Association,  
EASD = European Association for the Study of Diabetes,  
NCEP = National Cholesterol Education Panel, NSA = No specific amount,  
NRGU = Not recommended for general use, R = Recommended  
(Adopted from Ajala, O., English, P. & Pinkney, J., 2013) 
 
 
2.4.3 Physical activity 
Physical activity is defined as bodily movement of the contraction of the skeletal 
muscle and subsequently increase the energy expenditure (Colberg et al., 2010). The 
term “exercise” is referred to the repetition of bodily movement to maintain or 
improve physical fitness such as aerobic capacity, muscle strength or endurance, 
flexibility of the body (Zanuso et al., 2010). There are numerous studies on the effect 
Variables  ADA  AHA  BDA  EASD CDA Japan  
South 
Africa  
Indi
a  NCEP  
Carbohydrates 
(%) 50-60 45-55 50-55 45-60 50-60 60 55-60 > 65 50-60 
Fibre  NSA 
≥ 25 
g/d 
<30 
g/d 
Increase 
with low 
GI foods 
25-35 
g/d 
1 fruit, 
400g 
vegetables  40 g/d NSA 
20-30 
g/d 
Protein (%) 15-20 15 10-15 10-20 11 15-20 12-20 NSA 15 
Fat (%) 25-35 < 30 30-35 ≤ 35 ≤ 30 20-25 < 30 <21 25-35 
GI (%) NRGU - - R R R R - - 
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of aerobic exercise (AE) on improving glycaemic control (Ibañez et al., 2005, Irvine 
and Taylor, 2009, Snowling and Hopkins, 2006, Zanuso et al., 2010). In a meta-
analysis study that review regular AE at least eight weeks on T2DM patients has 
shown a significant reduction in HbA1c but not in the body weight (Boulé et al., 
2003). In a more recent meta-analysis study on the effect of AE on lipids and 
lipoprotein in T2DM patients also shown improvement in HbA1c whereas no 
significant reduction in lipid profile was found (Kelley and Kelley, 2007). Besides 
AE, the American College of Sports Medicine has recently recommended resistance 
training (RT) as a well-rounded exercise for T2DM patients. In one study conducted 
in newly diagnosed old man on a twenty-weeks supervised RT twice a week are able 
to reduce abdominal fat, increase muscle strength and improve insulin sensitivity 
(Ibañez et al., 2005). Another meta-analysis study shown that either AE alone or RT 
alone or a combination exercise have moderate effect on glycaemic control and small 
effect on other diabetes complication risk factors (Snowling and Hopkins, 2006). 
With all the evidences, it is recommended that T2DM patients should accumulate a 
minimum of 210 minutes of moderate-intensity exercise or 125 minutes of vigorous 
exercise every week with a combination of AE and RT (Hordern et al., 2012). 
Although AE or RT or a combination exercise is able to improve glycaemic control 
however, the choice of the types of exercise is depending on the co-morbidity, 
personal preference in T2DM patients and the availability of the resources (Irvine 
and Taylor, 2009).   
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2.5 Pharmacological treatment  
Pharmacological treatment will only be initiated when the lifestyle modification 
failed to achieve the targeted blood sugar level within 2-3 months (Canadian 
Diabetes Association Clinical Expert Committee, 2013). Currently, there are 
different types of pharmacological treatment available to treat T2DM. Table 2.3 
shows the pharmacological treatment options available for T2DM. However, the 
selection of pharmacological treatment for T2DM need to be individualized 
according to their specific factors (such as age, gender, BMI, duration of DM, waist 
circumferences and cardiovascular disease risk factors) and also mechanism action of 
various drugs on the targeted organs (Charbonnel and Cariou, 2011).   
 
Table 2.3 Pharmacological treatment options for type 2 diabetes mellitus  
Groups  Example of 
drugs  
Mode of action Advantages Disadvantages  
Biguanide  Metformin  Reduce hepatic 
glucose 
production and 
insulin 
resistance  
No weight gain 
and 
hypoglycaemia, 
Decrease in 
CVD events   
Gastrointestinal 
side effects 
(diarrhoea, 
abdominal 
discomfort), 
Vitamin B12 
deficiency 
Sulphonylurea  Gliclazide, 
Glibenclamide, 
Glimepiride, 
Glipizide, 
Glyburide  
Stimulate 
insulin release 
from pancreas 
β-cell  
Decrease in 
microvascular 
risk  
Hypoglycaemia, 
weight gain, 
possible blunt 
myocardial 
ischemic 
preconditioning, 
Low durability 
Alpha-Glucosidase 
Inhibitors 
 
Acarbose, 
Miglitol 
Slow intestinal 
carbohydrate 
digestion/absorp
tion  
No 
hypoglycaemia, 
decrease in post-
prandial glucose 
excursions, 
possible decrease 
in CVD event, 
non-systemic 
Modest reduction 
in HbA1c,  
Gastrointestinal 
side effects, need 
frequent dosing 
Thiazolidinediones Pioglitazone 
Rosiglitazone 
 
Increase insulin 
sensitivity 
 
No 
hypoglycaemia 
events, increase 
in HDL, 
Weight gain, 
oedema,  
bone fractures, 
increase in LDL, 
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decrease TG 
(Pioglitazone), 
possible to 
reduce CVD 
events  
possible to 
increase MI 
Meglitinides Repaglinide, 
Glinides, 
Nateglinide 
Stimulate 
insulin release 
from pancreas 
β-cell 
Decrease post-
prandial 
excursions, 
flexible dosing 
Hypoglycaemia, 
weight gain, 
possible blunts 
myocardial 
ischemic 
preconditioning, 
need frequent 
dosing 
Dipeptidyl 
peptidase four 
(DPP-4) inhibitors 
Sitagliptin, 
Linagliptin, 
Saxagliptin 
Increase insulin 
secretion 
(glucose-
dependent)  
Increase 
glucagon 
secretion 
(glucose-
dependent)  
No 
hypoglycaemia, 
well tolerated 
Modest reduction 
in HbA1c, 
urticarial / 
angioedema, 
possible 
pancreatitis  
Dopamine-2 
agonists  
Bromocriptine Modulates 
hypothalamic 
regulation of 
metabolism, 
Increase insulin 
sensitivity 
No 
hypoglycaemia. 
Decrease in 
CVD events  
Modest in HbA1c 
reduction, 
dizziness/ syncope, 
nausea, fatigue, 
rhinitis 
Glucagon-like 
peptide-1 (GLP-1) 
receptor agonists  
Exenatide,  
Liraglutide  
Insulin secretion 
(glucose-
dependent), 
Reduce 
glucagon 
secretion 
(glucose-
dependent), 
Slows gastric 
emptying, 
Increase satiety 
No 
hypoglycaemia, 
weight reduction, 
possible for 
improved β-cell 
mass/function, 
possible CV 
protective 
actions 
Gastrointestinal 
side effects, 
possible acute 
pancreatitis, 
injectable, training 
requirements 
Amylin mimetics  Praminitide Reduce 
glucagon 
secretion  
Slow gastric 
emptying, 
Increase satiety 
Decrease in post-
prandial glucose 
excursions, 
weight reduction 
Modest reduction 
in HbA1c, 
Gastrointestinal 
side effects need 
frequent dosing, 
injectable, 
hypoglycaemia 
unless insulin dose 
also reduced 
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Insulin Aspart, 
Detemir, 
Glargine, 
Glulisine, 
Human (NPH or 
regular), 
Lispro, 
Premixed 
Increase glucose 
disposal, 
Reduce hepatic 
glucose 
production 
Universally 
effective, 
Decrease in 
microvascular 
risk  
Hypoglycaemia, 
weight gain, 
possible mutagenic 
effects, injectable, 
training 
requirement, 
“Stigma” (for 
patients) 
(Adopted from Inzucchi et al., 2012)  
 
 
2.6 Prevalence of diabetes mellitus in Malaysia 
Malaysia is undergoing a transformation in the cause of morbidity from 
communicable diseases to non-communicable diseases (World Health Organization, 
2013b). In Malaysia, the prevalence of diabetes mellitus of adults aged > 30 years 
has increased from 6.3% to 14.9% within twenty years (Institute for Public Health, 
2011). The high prevalence of diabetes was mainly due to the population growth, 
urbanisation, changes in lifestyle, increased in physical inactivity and obesity (Wild 
et al., 2004). As shown in the Malaysian National Health Morbidity Survey III, 
higher prevalence was found in urban area compared to rural area. In the similar 
study, Indian ethnic group was found to have the highest prevalence were compared 
with other races (Institute for Public Health, 2011).  
 
2.7 Burden of diabetes mellitus in Malaysia 
Diabetes mellitus imposed a huge economic burden to the national healthcare system. 
Globally, a total of 490 billion will be expected to spend in healthcare in 2030 
(Zhang et al., 2010). Non-communicable diseases are one of the major health 
burdens in Malaysia (Disease Control Division, 2010). According to the statistic of 
causes of death in Malaysia, DM is one of the top ten leading causes of morbidity 
and mortality in the country (Department of Statistic Malaysia, 2010). The total 
burden for disease in 2000 was 2.8 million with more than two third was due to non-
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communicable diseases (Zainudin et al.). The complication of DM is one of the 
causes for disability and loss of life (Zhang et al., 2010). Because of its involvement 
in multiple organs, diabetes has significant impact to the individual, families and the 
society (International Diabetes Federation, 2013) .    
Malaysia is one of the few countries that offer a minimum charge for medical care 
for the people (World Health Organization, 2013b). However, the changes in the 
lifestyle have rapidly raised the healthcare cost in this country. Since 1990, Ministry 
of Health Malaysia has spent RM1.27 billion in healthcare and within 10 years the 
amount has increased to RM4.21 billion (Merican et al., 2004). Diabetes mellitus 
imposed financial burden to the individual with the disease, the family members, the 
society as well as the healthcare system (International Diabetes Federation, 2013). . 
For the year of 2000, the total burden of disease was accounted for 2.8 million 
disability adjusted life with 69% was contributed by non-communicable disease 
(NCD) (World Health Organization, 2013b). The increased in the disease has caused 
a vast increased in expenditure for anti-diabetes medications in Malaysia. As in 2008, 
the total cost spent in diabetes medications in the public sectors was RM 86,423,000 
compared to  RM 84,489,000 in 2007 (Lian et al., 2013). Another study conducted in 
an outpatient clinic of a teaching hospital in Kelantan has demonstrated that the 
estimated average of direct treatment cost for T2DM was RM 861.35 (USD 572.7) 
per patient per year (Ibrahim et al., 2010).  
 
2.8 Current healthcare system approach in managing diabetes mellitus  
In Malaysia, the healthcare system mainly can be divided into public, private sectors 
and non-government organisations (Merican et al., 2004). The public sectors are the 
main provider for the healthcare system in Malaysia and it is operated according to 
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the WHO model for district health system. In each typical district, there would be a 
district hospital with a few number of public primary care clinics. These public 
primary care clinics provide mainly ambulatory care services such as acute medical 
care, antenatal and postnatal care and non-communicable diseases management such 
as diabetes mellitus (Yasin et al., 2012). In 2002, the Innovative Care for Chronic 
Conditions (ICCC) Framework has been adapted from the Chronic Care Model 
(CCM) to improve the ambulatory care in the public primary care clinics in treating 
long term chronic diseases. Realizing the increased in the epidemic of the chronic 
diseases such as diabetes mellitus, Malaysian government have incorporated 
different professionals such as dietitians, pharmacists, physiotherapists and diabetic 
educators in the public primary care clinics to manage chronic diseases (Coleman et 
al., 2009). Thus, in the recently year, there was multiple disciplinary in the public 
primary care clinics to cater for the needs in chronic disease management. 
The public primary care clinics are heavily subsidised by the government and are 
delivered almost free of charge with a minimal charge of RM 1 for outpatients clinics 
and RM 5 for specialist consultations.  
     
2.9 Medication adherence in diabetes mellitus 
Type 2 DM is a complex metabolic disease that required multiple medications and 
lifestyle changes to reduce the blood sugar, cardiovascular risk and other 
comorbidities (Bailey and Kodack, 2011). Thus, polypharmacy is common among 
these groups of people (Grant et al., 2003). Studies have indicated that multiple doses, 
increased number of tablets and concurrent used of other medications are associated 
with low level of adherence (Melikian, 2002, Vanderpoel et al., 2004). There is no 
consensus on the adherence rate for chronic diseases to be considered as adequate 
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adherence. Some trials considered the adherence rate to be > 80% , whereas others 
considered 95% to be considered as adequate adherence (Osterberg and Blaschke, 
2005). The adherence rate for prescribed medication for diabetes mellitus vary from 
36-93% in worldwide (Wabe et al., 2011). According to WHO, non-adherence to 
medication is accounted for 50% of the chronically ill patients (World Health 
Organization, 2003). Recently, a systematic review has shown that the average 
adherence rate for oral anti-hyperglycaemia (OHA) was 36-93% (Cramer, 2004). 
Non-adherence to medications often led to suboptimal of glycaemic control 
(Rozenfeld et al., 2008). Addition to that, inadequate adherence to medications has 
imposed not only significant poor clinical outcomes but also the economic burden to 
the healthcare system (Cramer, 2004). Many studies in diabetes mellitus have proved  
that lower level of medication adherence associated with poor clinical outcomes (Ho 
et al., 2006, Howteerakul et al., 2007, van Bruggen et al., 2009, Pladevall et al., 2004) 
and higher cost of medical care (Sokol et al., 2005).  
 
2.10 Awareness and knowledge about diabetes mellitus  
Patients with chronic diseases such as T2DM required long term and sustainable 
disease management and prevention. Type 2 DM is a self-managed disease which 
required the patients to make decision on their daily dietary intake, medication 
adherence, physical activity and blood sugar monitoring. It is not easy to make 
decision without self-efficacy from the patients (Atak et al., 2008). In order for 
patients to be self-managed, patients must be well equipped with the knowledge of 
the disease, the importance of the management of the disease and the ability to solve 
problems (Murata et al., 2003). However, not many T2DM patients were aware of 
the disease itself and the management (Mohan et al., 2005). One of the study 
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conducted in Southern India has shown that patients with diabetes were not aware of 
the cause of the disease and the importance of healthy lifestyle (Murugesan et al., 
2007). Similarly in a study conducted at a tertiary hospital in Malaysia has shown 
that 26% of the problem encountered was due to insufficient awareness on disease 
(Huri and Wee, 2013) .  
Adequate knowledge and awareness on the disease can prevent patients from 
diabetes comorbidities (Moodley and Rambiritch, 2007). Thus, diabetes self-
management education (DSME) is important in helping patients to optimize the 
blood sugar control, prevent acute and chronic complications, improve quality of life 
and reduce unnecessary healthcare cost (Norris et al., 2002). A study conducted to 
assess the effectiveness of diabetes education in T2DM using the knowledge and 
awareness (KA) questionnaire has indicated that patients who have undergone a 
proper diabetes education have significant lower HbA1c and BMI compared to those 
who did not attended the education session (Ozcelik et al., 2010).  
 
2.11 Intervention to improve awareness and medication adherence in diabetes  
        mellitus  
 
Polypharmacy and complexity of regimens are one of the contributing factors to non-
adherence. Interventions of simplifying the regimens such as once daily dosing 
instead of twice daily dosing (Christopher M.D. et al., 2002) and fixed dose regimens 
(Melikian, 2002) have shown improvement in patients medication adherence. In one 
meta-analysis of the comparison between the fixed dose combination and free-drug 
regimens has indicated that fixed dose combination regimen has reduced non-
adherence of medications by 24-26% (Bangalore et al., 2007). In another study to 
evaluate the effectiveness of a simple and brief integrated approach has indicated that 
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there was a significant improvement in adherence in OHA and anti-depression agents 
in the intervention group (Bogner et al., 2012).  
In addition to that, patients’ awareness and knowledge on the disease and treatment 
have association with medication adherence (Al-Qazaz et al., 2011). A focus group 
study has explored T2DM patients’ perception on the problems they faced with non-
adherence to medications. Insufficient information provided by the doctors and the 
lack of knowledge on the disease were part of the reasons that they did not adhere to 
the prescribed regimens in that study (Vermeire et al., 2003). Studies on patients’ 
education and telephone follow-up (Piette et al., 2000) or short message services  
have shown improvement in patients’ knowledge and thus promote medication 
adherence (Zolfaghari et al., 2012). However, the ability of the patients to 
comprehend to treatment regimens was often overestimated as well. Studies have 
demonstrated that less than 50% of what the patients were told by the doctors was 
unable to recall and comprehend by the patients (Schillinger et al., 2002). Assessing 
patients’ recall and comprehension by the physicians is one of the strategies to 
enhance adherence (Rubin, 2005).    
Several interventions have been tested on the impact towards the improvement of 
medication adherence in T2DM. However, McDonald et al. have conducted a 
systematic review on all RCT interventions that intended to improve patients 
medication adherence has shown that strategies to improve medication adherence in 
chronically ill patients were complex, expensive and unable to predict the 
effectiveness (McDonald et al., 2002). It is complicated to perform an accurate 
adherence measurement, furthermore adherence varied over time (Vermeire et al., 
2001).  Up to now, there is no standard method to enhance medication adherence.  
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2.12 Drug-related problems in diabetes mellitus  
Drug related problem or medication-related problem is the broadest scope of 
addressing the vitality problems in the medicine use (Ackroyd-Stolarz et al., 2006). 
According to the Pharmaceutical Care Network Europe, drug related problem is 
defined as “an event or circumstance involving drug therapy that actually or 
potentially interferes with desired health outcomes” (Pharmaceutical Care Network 
Europe Foundation, 2006). In order to consider an event as DRP, the patient must 
either experiencing or about to experiencing the undesirable outcomes and the 
conditions have to be related to drug therapy (Strand et al., 1990). Drug related 
problems can be occurred during medications prescribing phase, medications 
dispensing phase or medications use phase by patients (van Mil, 2005).    
In patients with T2DM, often complex medications were prescribed to achieve 
optimal blood pressure, sugar and lipid level. Multiple regimens used have been 
linked to the high risk of the occurrence of drug related problems (DRP) (Viktil et al., 
2007). Although the prescribed medications are clinically justified, patients often 
seek alternative treatment (Stawicki and Gerlach, 2009). There are over the counter 
medications, supplements and traditional products sold in numerous palaces such as 
pharmacies and groceries shops which patients can easily buy without a prescription 
(Glintborg et al., 2004). Many patients with chronic disease such as T2DM often 
have more than one healthcare provider to treat their disease and received multiple 
prescriptions. Little or lacking of patients information sharing between the healthcare 
providers can lead to drug related problems (Stawicki and Gerlach, 2009).  
In Malaysia, there is an increasing trend of adverse reactions cases reported every 
year. In 2012, there were 10102 cases of adverse drug reactions reported compared to 
2011 there were 9385 cases reported (National Pharmaceutical Control Bureau 
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Ministry of Health Malaysia, 2012). Not only the prescribed medications that can 
lead to adverse drug reactions, there were 151 cases reported on traditional products 
used in 2012 (National Pharmaceutical Control Bureau Ministry of Health Malaysia, 
2013). The increased trend of the cases of adverse drug reactions has led to higher 
healthcare cost.  
Studies have conducted to identify drug-related problems in T2DM patients. In 
Switzerland, the authors found out that 26 (48.1%) of DM patients had encountered 
with ADE since they started the regimens (Eichenberger et al., 2011). In Brazil, a 
study to evaluate the effectiveness of pharmaceutical care program on T2DM 
patients has identified an average of 6.7 drug-related problems at baseline with 
majority was due to ineffective drugs (Mourão et al., 2012). Another study conducted 
in a tertiary hospital in Malaysia has indicated that majority of the T2DM with 
dyslipidaemia patients have potential interaction on the medications, non-adherence 
and lack of awareness (Huri and Ling, 2013).   
 
2.13 Pharmacist role in diabetes management 
The dramatic increase in new diabetes mellitus cases have put physician in a 
straining position to treat the patients. More time is required for the physician to 
manage chronic cases.  However, primary care physicians have little time to spend 
with patients with chronic diseases rather than patients with acute conditions 
(Campbell, 2002). As shown in one study to estimate the time required for the 
primary healthcare providers to provide high quality healthcare services for chronic 
cases has indicated that physicians need to spend at least 3.5 hours of every working 
day to provide the service (Østbye et al., 2005). Thus, pharmacists who are well-
trained and able to spend time with patients can help in solving the problem. 
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Pharmacists have been actively playing an important role in identifying, educating, 
assessing, referring and monitoring in diabetes management (Campbell, 2002). Many 
studies have supported the effectiveness of adding pharmacist in diabetes 
management in hospital, clinics and community settings. In one of the randomised 
controlled studies on pharmaceutical care model conducted by pharmacists has 
shown improvement in patients’ medication adherence and glycaemic control 
(Chung et al., 2014). In the Asheville Project, pharmacists provided education, self-
monitoring blood glucose (SMBG) training, monitoring and follow-up to diabetes 
patients has reduced patients’ HbA1c and all diagnosis costs (Cranor and Christensen, 
2003). Another study that aimed to evaluate the effectiveness of the collaboration 
between the physicians and pharmacists on uncontrolled diabetes patients has 
improved lipid and glycaemic control (Ramser et al., 2008). Similarly in  the study 
conducted in Sioux City, Iowa, pharmacists have group sessions appointment with 
the patients, medication reviews and telephone follow-up have shown a significant 
reduction by 1.7%  of  HbA1c within 9 months (Scott et al., 2006).  
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CHAPTER 3: GENERAL METHODOLOGY 
 
3.1 Introduction 
This chapter briefly described the overview of general quantitative study design and 
further outline the types of non-experimental, experimental designs, randomisation 
procedures and finally the summary of the method used in this study. 
 
3.2 Quantitative study design 
A quantitative study approach is one of the ways the researchers used post-positivist 
claims to develop information, employed strategies in seeking truth such as 
experiments and surveys, and collects information that yield statistical data (Creswell, 
2003). A quantitative method is on interest to maximize the objectivity, the 
generalizability and the replicability of the results (Harwell, 2011). Basically, a 
quantitative study can be categorised into two categories: non-experimental study 
and experimental study.      
 
3.2.1 Non-experimental  
Non-experimental study design has no randomisation process, manipulation of the 
study variables and comparison group. The researchers observe what happened 
naturally without any intervention imposed. Thus, non-experimental design is similar 
to post-test only experiment (Sousa et al., 2007). With that, non-experimental design 
can be classified into:  
(i) Cohort study design: This study determines the incidence, causes and 
prognosis of a natural condition. It measures the event in a temporal time 
that enables it to distinguish between causes and effects.      
24 
 
(ii) Cross-sectional study design: This study mainly determines the 
prevalence of a population at a single point of time.        
(iii) Case-control study design: This study normally conducted retrospectively 
and determines the factors that can contribute to the condition by 
comparing the group of people with the condition with the group of 
people without the condition (Mann, 2003). 
 
3.2.2 Experimental  
An experimental study design follows a randomisation process, manipulation of the 
study variables and presents comparison of groups. It examines the cause-
relationships effect of the study variables (Sousa et al., 2007). An experimental 
design can be further divided into: 
(i) True-experimental design: In this design, the process of randomisation 
must take place with the presence of comparison group and manipulation 
of the study variables. The design is useful in addressing the evaluation 
on the effectiveness and impact of a program. The most common true-
experimental design are post-test only comparison group, pre-test post-
test comparison group, Soloman four groups and cross-over designs 
(Pamela J. Brink).  
(ii) Quasi-experimental design: In this design, anyone of the key elements in 
the true-experimental design is absent, especially the random assignment 
of the groups. The design is useful as well in evaluating the effectiveness 
or the impact of a program. However, there are lack of confidence and 
generalizability in the findings. Example of commonly used quasi-
experimental designs are non-equivalent group pre-test post-test group 
